Sign In
Buy GSK
$51.53
+0.0200 (+0.0388%)
At Close: Aug 04, 2026
GSK's Myelofibrosis Candidate MAA Gets Accepted in Europe
12:02pm, Monday, 05'th Dec 2022
GSK's new drug application (NDA) for momelotinib is under standard FDA review, with a decision expected on Jun 16, 2023.
GSK gets price target cut from Citi as Zantac cloud lingers
04:52am, Friday, 02'nd Dec 2022
Analysts at Citi have lowered their price target for GSK PLC (LSE:GSK, NYSE:GSK) to 1,545p from 1,975p to reflect the limited visibility investors enjoy over the ultimate magnitude of Zantac ulcer
GSK delivers double dose of positive cancer drug news
03:51am, Friday, 02'nd Dec 2022
GSK PLC (LSE:GSK, NYSE:GSK) shares fell despite a double dose of positive news, with the EU medical regulator accepting its application for a myelofibrosis treatment and success in a Phase-3 endometri
GSK Phase 3 trial for Jemperli endometrial cancer treatment met primary endpoint
02:56am, Friday, 02'nd Dec 2022
GSK PLC said Friday that a Phase 3 trial for its Jemperli treatment for advanced or recurrent endometrial cancer met its primary endpoint, showing meaningful improvement in progression-free survival.
GSK plc (GSK) Presents at 5th Annual Evercore ISI HealthCONx Conference 2022
10:22am, Wednesday, 30'th Nov 2022
GSK plc (NYSE:GSK ) 5th Annual Evercore ISI HealthCONx Conference 2022 November 30, 2022 8:00 AM ET Company Participants Deborah Waterhouse - Chief Executive Officer, ViiV Healthcare Kimberly Smith -
PRO Watch DCLA's Sarat Sethi break down stocks to watch, markets
08:12am, Tuesday, 29'th Nov 2022
Sarat Sethi, managing partner and portfolio manager at DCLA, joins CNBC's 'Squawk Box' to break down potential market strategies and stocks to watch ahead of the open. Sethi also breaks down how he's
GSK to withdraw Blenrep's U.S. marketing authorization after FDA request
03:42am, Tuesday, 22'nd Nov 2022
GSK PLC GSK, +0.87% said Tuesday that it has started the withdrawal process of the U.S. marketing authorization for its Blenrep treatment, following the request of the country's Food and Drug Administ
GSK halts US marketing process for Blenrep after recent disappointing trial data
02:34am, Tuesday, 22'nd Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) has started for withdrawal process for US marketing authorisation for Blenrep following a request of the US Food and Drug Administration (FDA). The request followed th
GSK plc (GSK) 13th Annual Jefferies London Healthcare Conference 2022 (Transcript)
09:36pm, Friday, 18'th Nov 2022
GSK plc (NYSE:GSK ) 13th Annual Jefferies London Healthcare Conference 2022 November 16, 2022 4:45 AM ET Company Participants David Redfern - Chief Strategy Officer Conference Call Participants Peter
GSK shares lower as UBS downgrades pharma giant to sell
06:41am, Friday, 11'th Nov 2022
Shares of GSK GSK, -3.85% fell nearly 4% in London as UBS downgraded the pharmaceutical giant to sell from neutral. “We see two factors posing risks to the earnings base longer term – blockbuster
GSK slapped with 'sell' rating over long-term risks
06:32am, Friday, 11'th Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) shares have been slapped with a 'sell' rating by UBS, which downgraded its recommendation as it sees two big long-term risks ahead. Admittedly, the risks are all the way
GSK: Near-Term Upside
04:58am, Friday, 11'th Nov 2022
British pharmaceutical company GSK has seen an 8% price rise since I wrote about it a little over a month ago. What has driven this? Its upgraded earnings outlook and approvals for its treatments have
GSK second-line applications of new cancer drug will be restricted
02:28am, Friday, 11'th Nov 2022
GSK PLC (LSE:GSK, NYSE:GSK) said the second-line applications of its cancer drug will be limited in scope. The front-line use of Zejula, which has been developed to treat epithelial ovarian, fallopian
GSK spinoff Haleon lifts guidance as revenue rises on higher sales and volumes
02:50am, Thursday, 10'th Nov 2022
By Michael Susin
Bert's October Dividend Income Summary
09:53pm, Wednesday, 09'th Nov 2022
We received $801.63 in October dividend income. This was the first quarter we received a dividend from Vanguard's S&P 500 Index fund (VOO).
